ZMUni Compliance Centre

ZMUni Compliance Centre

导航菜单
ZMUni Compliance Centre
Success Story | ZMUni Supports Cosmetic Compliance Projects Across Global Markets
Congrats! ZMUni Supports XtalPi in Achieving U.S. Self-Affirmed GRAS Certification for Novel Food Ingredient Tensotide™
Global Cosmetic Regulatory Updates in June 2026
Global Food Regulatory Updates in June 2026
China's Non-compliant Food Imports in May 2026: A Closer Look at the Sodium Metabisulfite Surge
Leveraging China's Local Policy Incentives: How Imported Cosmetics Can Benefit
previous arrowprevious arrow
next arrownext arrow
 
Industry Insights 资讯/缺省
China's NCI Approval Updates: Peptides, Botanicals & Biotechnology Innovations

   From July 1 to 7, a total of five new cosmetic ingredients completed notification with China's National Medical Products Administration (NMPA). The technical requirements for all related NCIs have not been publicly disclosed.      S-{8-[(4,4,4-trifluorobutyl)sulfanyl]octyl}(2,3-dihydroxyphenyl)methanethioate (Notification No.2026018)   S-{8-[(4,4,4-trifluorobutyl)sulfanyl]octyl}(2,3-dihydroxyphenyl)methanethioate is a chemically synthesized cosmetic ingredient. Based on efficacy tests and in vitro studies, it can help improve TEWL, skin softness, and hair shine, and may be used as a skin protectant, emollient, and hair conditioning agent.   With regulatory support from ZMUni Compliance Centre, this ingredient completed its NCI notification and entered the public disclosure stage, marking the

时间
2026-07-08
ChinaCosmetics
View
Industry Insights 资讯/缺省
China's NCI Approval Updates: Six Notified, Two Photoinitiators Included

    During the last week of June 2026, a total of six new cosmetic ingredients completed notification with China's National Medical Products Administration (NMPA). The technical requirements for all related NCIs have not been publicly disclosed.     Ginsenoside Compound K (Notification No.20260111)   According to the notifier Giant Biogene, this Ginsenoside Compound K adopts a differentiated production pathway, integrating an enzyme-directed biotransformation process with high-purity preparative separation technology for rare ginsenosides.   The notified ingredient is positioned for skin barrier repair and sebum regulation, addressing key concerns in oily and acne-prone skin.     Photoinitiators (Notification No.20260113 and

时间
2026-07-01
ChinaCosmetics
View
Industry Insights 资讯/缺省
China's NCI Approval Updates: Spotlight on Fungal Ingredients

From June 15 to June 23, 2026, 7 new cosmetic ingredients (NCIs) have completed notifications with China's National Medical Products Administration (NMPA). The technical requirements have not been disclosed yet.     Polymers   Notification No. 20260104  Hydrogenated Soy Polyglycerides is the product obtained through catalytic metathesis of Glycine Soja (Soybean) Oil, followed by hydrogenation. According to PCPC, its functions include Skin-Conditioning Agent (Occlusive) and Viscosity Increasing Agent (Nonaqueous). This notification marks the first NCI submission from a Singapore-based company under China's NCI framework.   Notification No. 20260105 and Notification No. 20260106 In this issue, Intercos S.p.A. notified two NCIs, both

时间
2026-06-24
ChinaCosmetics
View
Industry Insights 资讯/缺省
Navigating Compliance for Plant-Derived Vesicles and Exosome-like Ingredients in China

"Plant-derived exosomes" have become a focal point in global cosmetic ingredient innovation due to their natural origin, biocompatibility, and targeted delivery capabilities. However, as an emerging bio-based ingredient, they still face significant regulatory hurdles in China—including scientific nomenclature, classification as "New Cosmetic Ingredients" (NCI), and the design of appropriate notification and registration pathways.   This article provides a structured overview of how these materials are currently understood under China’s regulatory framework, with reference to international nomenclature practices and key compliance considerations.     01. Nomenclature: The "Vesicle" vs. "Exosome" Distinction   Under the International Nomenclature of Cosmetic Ingredients (INCI) framework,

时间
2026-06-24
ChinaCosmetics
View
Industry Insights 资讯/缺省
China's NCI Approval Updates: Peptides, Botanicals & Functional Molecules

  From June 8 to June 12, 2026, 7 new cosmetic ingredients (NCIs) have completed notifications with China's National Medical Products Administration (NMPA).     Peptides   Notification No. 20260097 - sr-(Tripeptide-133 sh-Polypeptide-2 Hexapeptide-40)   According to the publicly available patent filed by the notifier (CN120918980A), sr-(Tripeptide-133 sh-Polypeptide-2 Hexapeptide-40) demonstrates strong antioxidant activity and can act synergistically with other active ingredients. It enables the development of a new, high-performance active ingredient system applicable in both skincare and hair care products, enhancing antioxidant and repair-related efficacy.     Notification No. 20260100   Hexapeptide-125 (translated from Chinese name, official INCI name currently

时间
2026-06-15
ChinaCosmetics
View
Industry Insights 资讯/缺省
China's NCI Approval Updates: White Rose, Marine Algae and More

  From May 26 to June 3, 2026, 6 new cosmetic ingredients (NCIs) have completed notifications with China’s National Medical Products Administration (NMPA).     Rosa Alba Flower Water   Rosa alba (White Rose) is a classic botanical prized for centuries in both Eastern and Western cultures. Renowned for its delicate fragrance and pure white blossoms, it has traditionally been used in soothing skincare and aromatic applications, combining natural beauty with botanical care.     Pyropia Haitanensis Extract   Pyropia haitanensis is an edible red algae mainly found along the southeastern coast of China, particularly in Zhejiang and Fujian provinces.

时间
2026-06-04
ChinaCosmetics
View
Industry Insights 资讯/缺省
China's NCI Approval Updates: Targeted Plant Cell Culture Innovation and Cyclic Peptides

  From May 13 to 22, 2026, 7 new cosmetic ingredients (NCIs) have completed notifications with China's National Medical Products Administration (NMPA).      Plant & Biotech   Notification 20260084 - Saussurea Involucrata Callus Extract This NCI was notified by a subsidiary of Veminsyn Biotech (Zhejiang), with compliance support provided by ZMUni Compliance Center. ZMUni previously assisted Veminsyn Biotech in successfully notifying another NCI, Epiphyllum oxypetalum Callus Extract, continuing to safeguard the compliant commercialization of the company's innovations.   The primary active components of Saussurea involucrata are flavonoids and polysaccharides, alongside alkaloids, organic acids, ceramides, volatile oils, trace elements, and

时间
2026-05-25
ChinaCosmetics
View
Industry Insights 资讯/缺省
Exosomes in Cosmetics: From Hype to Regulatory Reality

Following China's 2026 "315 Gala" - the country's annual consumer rights program known for exposing market misconduct - the once-booming exosome trend in cosmetics and medical aesthetics has rapidly cooled in China.   But the real story is not the decline of a technology. It is the correction of a market driven by aggressive commercialization, exaggerated claims, and increasingly blurred compliance boundaries.   As the industry moves beyond the hype cycle, exosomes in China are entering a new phase - one shaped less by marketing narratives and more by scientific validation, regulatory expectations, and long-term viability.   What Regulators Are Targeting Is the Misuse of

时间
2026-04-30
ChinaEUUSACosmetics
View